Aphria Awarded Provisional Approval in Germany for Cannabis Cultivation License

Published: April 8, 2019

Aphria Awarded Provisional Approval in Germany for Cannabis Cultivation License

Aphria Inc. announced that its German subsidiary Aphria Deutschland GmbH has been selected by the German Federal Institute for Drugs and Medical Devices to receive a license for the domestic cultivation of medical cannabis. The provisional decision announced by BfArM is subject to a mandatory 10-day standstill period for public contracts, which permits unsuccessful bidders to challenge the decision before the final contract is signed. BfArM’s decision would grant Aphria 5 of the 13 available lots, each with a minimum annual capacity of 200 kg.

“Aphria is proud to have been selected as a successful applicant in the German tender process, a testament to our high production quality standards,” said Hendrik Knopp, Managing Director of Aphria Germany. “The decision from BfArM is a validation of our strategic approach to supporting the German medical cannabis market, including with high-quality, domestic production to secure vital supply for patients. We are very pleased with our continued business momentum in Germany.”

Since Germany’s Cannabis as Medicines Act was enacted in March 2017, the country’s growing medical cannabis needs, currently estimated at up to 40,000 patients, has been exclusively supplied by imports. Pending the successful completion of the Standstill, Aphria looks forward to supplying German patients with domestically-grown, high-quality medical cannabis.